EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dapagliflozin Preserves Peripheral Nerve Structure and Reduces Neuropathic Damage in Streptozotocin-Induced Diabetic Peripheral Neuropathy

Anca-Maria Țucă, Alexandra Nicoleta Preda, Georgică Târtea, Diana-Ruxandra Hădăreanu iD, Eugen Țieranu, Alexandra Oltea Dan, Elena-Anca Târtea, Andrei Greșiță, Denisa Floriana Vasilica Pîrșcoveanu, Veronica Sfredel, Smaranda Ioana Mitran iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262412034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Anca-Maria Țucă und 10 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Research Centre for Normal and Pathological Aging, University of Medicine and Pharmacy of Craiova, 2 Petru Rares St., 200349 Craiova, Ro…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetic Neuropathies, Glucosides, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy of Craiova, Romania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes mellitus, driven by oxidative stress, inflammation, and microvascular dysfunction. Dapagliflozin, a selective inhibitor of sodium–glucose cotransporter type 2 (SGLT2), is used in the treatment of type 2 diabetes and has pleiotropic antioxidant and anti-inflammatory effects. The aim of this study was to evaluate the neuroprotective effects of dapagliflozin in an experimental model of streptozotocin (STZ)-induced diabetic peripheral neuropathy in mice. C57BL/6 mice were divided into three groups: control (DM–), STZ-induced diabetes (DM+), and diabetes + dapagliflozin (DM + DAPA, 10 mg/kg/day, oral administration for 12 weeks). Clinical (glycemia, weight, diuresis), electrophysiological, and histopathological parameters were evaluated, and behavioral tests (Open Field, Von Frey, Hot Tail) were performed. Dapagliflozin significantly reduced hyperglycemia, limited weight loss and polyuria, and improved locomotor behavior and nociceptive sensitivity. Electrodiagnostically, the treatment increased the amplitude and reduced the duration of motor potentials, indicating improved nerve conduction. Histological analyses showed decreased hydroxynonenal (HNE) immunoreactivity, suggesting attenuation of oxidative stress, reduced perineural fibrogenesis, and maintained intraepidermal nerve fiber density. Dapagliflozin exerts significant neuroprotective effects in experimental diabetic peripheral neuropathy by reducing oxidative stress, inflammation, and fibrosis and maintaining the structural and functional integrity of peripheral nerves.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsDiabetic NeuropathiesGlucosidesDiabetes Mellitus, ExperimentalPeripheral NervesNeuroprotective AgentsAnimalsMiceMaleMice, Inbred C57BLOxidative StressStreptozocinSodium-Glucose Transporter 2 InhibitorsNeural Conduction

Stichwörter der Autor:innen

dapagliflozindiabetes mellitusdiabetic peripheral neuropathyneuroprotectionoxidative stress

Substanzen

dapagliflozinBenzhydryl CompoundsGlucosidesStreptozocinNeuroprotective AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Experimental Research Centre for Normal and Pathological Aging, University of Medicine and Pharmacy of Craiova, 2 Petru Rares St., 200349 Craiova, Romania.
  • Department of Neurology, University of Medicine and Pharmacy of Craiova, 2 Petru Rares St., 200349 Craiova, Romania.
  • Department of Cardiology, University of Medicine and Pharmacy of Craiova, 2 Petru Rares St., 200349 Craiova, Romania.

ORCID-Profile: Diana-Ruxandra Hădăreanu, Smaranda Ioana Mitran

Förderung

  • University of Medicine and Pharmacy of Craiova, Romania

Zitieren

APA

Țucă, A. M., Preda, A. N., Târtea, G., Hădăreanu, D. R., Țieranu, E., Dan, A. O., Târtea, E. A., Greșiță, A., Pîrșcoveanu, D. F. V., Sfredel, V., & Mitran, S. I. (2025). Dapagliflozin Preserves Peripheral Nerve Structure and Reduces Neuropathic Damage in Streptozotocin-Induced Diabetic Peripheral Neuropathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262412034

Vancouver

Țucă AM, Preda AN, Târtea G, Hădăreanu DR, Țieranu E, Dan AO, et al. Dapagliflozin Preserves Peripheral Nerve Structure and Reduces Neuropathic Damage in Streptozotocin-Induced Diabetic Peripheral Neuropathy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262412034

BibTeX
@article{uc2025,
  author = {Țucă, Anca-Maria and Preda, Alexandra Nicoleta and Târtea, Georgică and Hădăreanu, Diana-Ruxandra and Țieranu, Eugen and Dan, Alexandra Oltea and Târtea, Elena-Anca and Greșiță, Andrei and Pîrșcoveanu, Denisa Floriana Vasilica and Sfredel, Veronica and Mitran, Smaranda Ioana},
  title = {Dapagliflozin Preserves Peripheral Nerve Structure and Reduces Neuropathic Damage in Streptozotocin-Induced Diabetic Peripheral Neuropathy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262412034}
}
Kostenlos starten →